EosGene Tx
Our Team
We bring together leading edge expertise in nanomedicine, liposome innovations, CRISPR design, genetic engineering and decades of experience
in IP and project management, business and high technology startups.
Dr. Yagiz Aksoy has over 15 years of experience in the translation and commercialisation of research. His strong background as a synthetic biologist, coupled with his expertise in CRISPR/Cas9, genome editing and gene therapy, has led him to develop novel genome engineering technologies and their commercial translation. A sought-after speaker, Dr. Aksoy was invited to present his technology over 50 institutes globally, including the US Department of Defence, US Office of Naval Research, Australian Defence Science Institute. Dr Aksoy has extensive experience in regulatory affairs, having researched and evaluated multiple health and medical research policy directives and programs to assess their impact on ethics and governance initiatives, and Ministry and Government objectives.
Dr Ewa Goldys is Scientia Professor at the University of New South Wales, Sydney, Australia. She is world leader in applications of light to biomedicine and nanotechnology. She won a number of Prizes and Fellowships including 2020 NSW Premier’s Award for Leadership in Innovation, 2020 Fellowship of Royal Society of NSW and 2016 Eureka Prize for Innovative Use of Technology. She has a proven track record of research translation, with over 10 patents filed and licensed. She raised over $70,000,000 of competitive funding (most as lead investigator) and over $ 15,000,000 of negotiated research funding.
Dr Wei Deng is Associate Professor of Nanomedicine at the University Technology Sydney, Australia. She has been awarded over $ 2.5 M of research funding including multiple fellowships. Her pioneering research spans the areas of nanotechnology and gene engineering. She created new liposomal strategies for drug/gene delivery. Her liposome engineering innovations have led to the development of an innovative treatment strategy for cancer patients who no longer benefit from standard-of-care chemo/radiotherapy due to their toxicities and limitations. In EosGene, she is leading the technical developments including production scale and validation of manufactured products.
John Martin has over 20-year experience as a director of and business advisor to private and public emerging technology companies. His experience spans startup creation, capital raising, R&D collaborations and out-licensing through to manufacturing and commercialisation. Mr Martin was former CEO of ASX listed Regeneus, Primelife and Babcock & Brown. He is a former corporate partner of law firm Allens. John is currently a Non-Executive Director of AiMedia TechnologiesHis current roles include Board Chairs at BioPoint and the Centre for Commercialisation of Regenerative Medicine (CCRM) Australia. In EosGene, he provides advice on the business development and governance related to research commercialisation.